(Source: XBiotech Inc) Improved clinical response seen for multiple symptoms associated with disease progression and overall survival, with notable lack of toxicity Xilonix is the first antibody therapy to neutralize biological activity of interleukin-1 alpha (IL-1α), a potent anti-inflammatory signaling molecule known to promote the growth and spread of tumors Xilonix granted accelerated review by the European Medicines Agency (EMA); an approval decision could come as early as fourth quarter 2016 AUSTIN, Texas, July 02, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ antibody therapies, today presented positive results from a pivotal Phase III...
↧